News / Press Release

Move your research forward, smarter with TD2

June 5, 2018
Don’t let good research go bad with a sloppy strategy. Think smarter with these tips to get every go-to-market plan in tip-top shape with faster data, quality care, and early clinical evidence.

1. Set the destination, but plan for detours.

For a smart kickoff strategy, you’ll need to keep tabs on more than you might think. For example, do you fully understand the genetic makeup of a patient’s tumor and what makes your drug a match? Will you enroll patients with that same genetic context?

You’ll also need to plan for every scenario and adapt your trial design in real-time based on the data. Ask yourself:

2. Build checkpoints into your trial.

It’s not just about the start, the middle and the end—it’s about all the mile markers in between. So, add intermediary goals to measure performance in real-time. That way, you can track progress for the many things a sound clinical strategy needs, like advanced diagnostics, comprehensive medical imaging and genetic targeting.

3. Assess and adapt in real-time.

Strategies can (and should) change in real-time. Go where the science takes you, and if that means you consider clinical sites, patient populations or indications you hadn’t thought of before, go for it. More nimble strategies make for the best clinical outcomes, so don’t be afraid to adapt as you go.

Ready to create your clinical strategy? Fast-track your research with TD2 and get the peace of mind of working with a partner who navigates the complexities of drug development to guide you down the smarter path. 

About Translational Drug Development (TD2)

TD2 is an oncology development organization that provides innovative services for oncology-focused companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit www.TD2inc.com.

About TD2

TD2 is an oncology development organization that provides innovative services for oncology-focused companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit www.TD2inc.com.

Contact
Tara Franks
602-358-8322
Get free tips, tools and resources by subscribing to the TD2 Newsletter: